Prescient Therapeutics Limited (ASX:PTX)

Market Cap	44.73M
Revenue (ttm)	4.36M
Net Income (ttm)	-7.32M
Shares Out	1.04B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	373,290
Average Volume	1,254,275
Open	0.0430
Previous Close	0.0430
Day's Range	0.0430 - 0.0430
52-Week Range	0.0370 - 0.0630
Beta	0.50
RSI	45.13
Earnings Date	Aug 22, 2025

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block a cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. It also develops personalised medicine approaches to cancer, including targeted and cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Li...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PTX

Financial Performance

In 2025, Prescient Therapeutics's revenue was 4.36 million, an increase of 17.35% compared to the previous year's 3.71 million. Losses were -7.32 million, -11.11% less than in 2024.